4.7 Article

Diagnostic Performance of Noninvasive Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography in Suspected Coronary Artery Disease The NXT Trial (Analysis of Coronary Blood Flow Using CT Angiography: Next Steps)

期刊

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 63, 期 12, 页码 1145-1155

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2013.11.043

关键词

computational fluid dynamics; coronary CT angiography; fractional flow reserve; invasive coronary angiography

资金

  1. HeartFlow, Inc.
  2. Abbott Vascular, Boston Scientific, Cordis, Medtronic, HeartFlow, Eli Lilly, Bristol-Myers Squibb, Daiichi Sankyo, and Sanofi-aventis
  3. Siemens, Guerbet, and Abbott
  4. St. Jude Medical, Boston Scientific, Radi, Terumo, and Volcano
  5. GE Healthcare
  6. Edwards Lifesciences
  7. British Heart Foundation [PG/11/55/28999] Funding Source: researchfish
  8. Novo Nordisk Fonden [NNF13OC0007447] Funding Source: researchfish

向作者/读者索取更多资源

Objectives The goal of this study was to determine the diagnostic performance of noninvasive fractional flow reserve (FFR) derived from standard acquired coronary computed tomography angiography (CTA) datasets (FFRCT) for the diagnosis of myocardial ischemia in patients with suspected stable coronary artery disease (CAD). Background FFR measured during invasive coronary angiography (ICA) is the gold standard for lesion-specific coronary revascularization decisions in patients with stable CAD. The potential for FFRCT to noninvasively identify ischemia in patients with suspected CAD has not been sufficiently investigated. Methods This prospective multicenter trial included 254 patients scheduled to undergo clinically indicated ICA for suspected CAD. Coronary CTA was performed before ICA. Evaluation of stenosis (>50% lumen reduction) in coronary CTA was performed by local investigators and in ICA by an independent core laboratory. FFRCT was calculated and interpreted in a blinded fashion by an independent core laboratory. Results were compared with invasively measured FFR, with ischemia defined as FFRCT or FFR <= 0.80. Results The area under the receiver-operating characteristic curve for FFRCT was 0.90 (95% confidence interval [CI]: 0.87 to 0.94) versus 0.81 (95% CI: 0.76 to 0.87) for coronary CTA (p = 0.0008). Per-patient sensitivity and specificity (95% CI) to identify myocardial ischemia were 86% (95% CI: 77% to 92%) and 79% (95% CI: 72% to 84%) for FFRCT versus 94% (86 to 97) and 34% (95% CI: 27% to 41%) for coronary CTA, and 64% (95% CI: 53% to 74%) and 83% (95% CI: 77% to 88%) for ICA, respectively. In patients (n = 235) with intermediate stenosis (95% CI: 30% to 70%), the diagnostic accuracy of FFRCT remained high. Conclusions FFRCT provides high diagnostic accuracy and discrimination for the diagnosis of hemodynamically significant CAD with invasive FFR as the reference standard. When compared with anatomic testing by using coronary CTA, FFRCT led to a marked increase in specificity. (HeartFlowNXT-HeartFlow Analysis of Coronary Blood Flow Using Coronary CT Angiography [HFNXT]; NCT01757678) (C) 2014 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据